<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Grail, Llc — News on 6ix</title>
<link>https://6ix.com/company/grail-llc</link>
<description>Latest news and press releases for Grail, Llc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/grail-llc" rel="self" type="application/rss+xml" />
<item>
<title>GRAIL to Announce First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/grail-llc/news/grail-to-announce-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-to-announce-first-quarter-2026-financial-results</guid>
<pubDate>Wed, 22 Apr 2026 20:01:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.</description>
</item>
<item>
<title>GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide</title>
<link>https://6ix.com/company/grail-llc/news/grail-announces-integration-of-the-gallerir-test-into-epic-electronic-health-record-platform-to-expand-access-nationwide</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-announces-integration-of-the-gallerir-test-into-epic-electronic-health-record-platform-to-expand-access-nationwide</guid>
<pubDate>Tue, 07 Apr 2026 20:01:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Epic to bring the Galleri® multi-cancer early detection test into one of the nation's most widely used electronic health record (EHR) platforms, supporting broader adoption across health systems in the United States.</description>
</item>
<item>
<title>Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection</title>
<link>https://6ix.com/company/grail-llc/news/cancer-is-striking-earlier-superpower-and-grail-are-partnering-to-expand-early-detection-2</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/cancer-is-striking-earlier-superpower-and-grail-are-partnering-to-expand-early-detection-2</guid>
<pubDate>Wed, 01 Apr 2026 17:08:00 GMT</pubDate>
<description>Superpower, the first all-in-one proactive health platform, announced a strategic partnership with GRAIL, Inc. (Nasdaq: GRAL) to bring members access to the Galleri® multi-cancer early detection (MCED) test. Timed with the start of National Cancer Prevention and Early Detection Month, the partnership reflects a shared belief that cancer detection must evolve to meet a changing reality — removing traditional barriers to advanced testing and putting earlier insight, data, and control directly in p</description>
</item>
<item>
<title>GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor</title>
<link>https://6ix.com/company/grail-llc/news/grail-announces-retirement-of-ceo-bob-ragusa-and-appointment-of-josh-ofman-md-mshs-as-successor</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-announces-retirement-of-ceo-bob-ragusa-and-appointment-of-josh-ofman-md-mshs-as-successor</guid>
<pubDate>Thu, 12 Mar 2026 20:30:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a</description>
</item>
<item>
<title>GRAIL to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/grail-llc/news/grail-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 21:02:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m. ET.</description>
</item>
<item>
<title>GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/grail-llc/news/grail-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Feb 2026 21:02:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 and provided business updates.</description>
</item>
<item>
<title>Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate</title>
<link>https://6ix.com/company/grail-llc/news/landmark-nhs-galleri-trial-demonstrates-a-substantial-reduction-in-stage-iv-cancer-diagnoses-increased-stage-i-and-ii-detection-of-deadly-cancers-and-four-fold-higher-cancer-detection-rate</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/landmark-nhs-galleri-trial-demonstrates-a-substantial-reduction-in-stage-iv-cancer-diagnoses-increased-stage-i-and-ii-detection-of-deadly-cancers-and-four-fold-higher-cancer-detection-rate</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced topline results from the landmark, randomized, controlled NHS-Galleri trial, which evaluated annual multi-cancer screening with the Galleri® test in England's National Health Service (NHS) over three years in 142,000 demographically representative participants aged 50 to 77.</description>
</item>
<item>
<title>GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/grail-llc/news/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 16 Feb 2026 14:00:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year 2025 following the close of market on Thursday, Feb. 19, 2026. Following the release, company management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress.</description>
</item>
<item>
<title>GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test</title>
<link>https://6ix.com/company/grail-llc/news/grail-submits-fda-premarket-approval-002500947</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-submits-fda-premarket-approval-002500947</guid>
<pubDate>Fri, 30 Jan 2026 00:25:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Galleri® multi-cancer early detection (MCED) test. The FDA designated the test as a Breakthrough Device in 2018.</description>
</item>
<item>
<title>GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/grail-llc/news/grail-present-44th-annual-j-210100685</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-present-44th-annual-j-210100685</guid>
<pubDate>Mon, 15 Dec 2025 21:01:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT.</description>
</item>
<item>
<title>GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/grail-llc/news/grail-announces-inducement-grants-under-210100162</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-announces-inducement-grants-under-210100162</guid>
<pubDate>Mon, 01 Dec 2025 21:01:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form</description>
</item>
<item>
<title>GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/grail-llc/news/grail-present-piper-sandler-37th-210200252</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-present-piper-sandler-37th-210200252</guid>
<pubDate>Tue, 18 Nov 2025 21:02:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2 at 3:00 p.m. ET.</description>
</item>
<item>
<title>GRAIL Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/grail-llc/news/grail-reports-third-quarter-2025-210200325</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-reports-third-quarter-2025-210200325</guid>
<pubDate>Wed, 12 Nov 2025 21:02:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025.</description>
</item>
<item>
<title>GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference</title>
<link>https://6ix.com/company/grail-llc/news/grail-present-7th-annual-wolfe-210200289</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-present-7th-annual-wolfe-210200289</guid>
<pubDate>Tue, 04 Nov 2025 21:02:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18 at 10:00 a.m. ET.</description>
</item>
<item>
<title>GRAIL to Announce Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/grail-llc/news/grail-announce-third-quarter-2025-200200234</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-announce-third-quarter-2025-200200234</guid>
<pubDate>Wed, 29 Oct 2025 20:02:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following the close of market on Wednesday, Nov. 12, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.</description>
</item>
<item>
<title>GRAIL, Inc. Announces $325.0 Million Private Placement Financing</title>
<link>https://6ix.com/company/grail-llc/news/grail-inc-announces-325-0-103000085</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-inc-announces-325-0-103000085</guid>
<pubDate>Mon, 20 Oct 2025 10:30:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents' fees and other expenses.</description>
</item>
<item>
<title>/U P D A T E -- GRAIL, Inc./</title>
<link>https://6ix.com/company/grail-llc/news/u-p-d-t-e-090300475</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/u-p-d-t-e-090300475</guid>
<pubDate>Sat, 18 Oct 2025 09:03:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251.</description>
</item>
<item>
<title>GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings</title>
<link>https://6ix.com/company/grail-llc/news/grail-pathfinder-2-results-show-220800083</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-pathfinder-2-results-show-220800083</guid>
<pubDate>Fri, 17 Oct 2025 22:08:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251.</description>
</item>
<item>
<title>Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia</title>
<link>https://6ix.com/company/grail-llc/news/samsung-grail-announce-strategic-collaboration-122200428-1</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/samsung-grail-announce-strategic-collaboration-122200428-1</guid>
<pubDate>Thu, 16 Oct 2025 12:22:00 GMT</pubDate>
<description>Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL's GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of $70.05 per share of common stock.1</description>
</item>
<item>
<title>GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC</title>
<link>https://6ix.com/company/grail-llc/news/grail-present-galleri-data-more-130100236</link>
<guid isPermaLink="true">https://6ix.com/company/grail-llc/news/grail-present-galleri-data-more-130100236</guid>
<pubDate>Tue, 23 Sep 2025 13:01:00 GMT</pubDate>
<description>GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the Galleri® multi-cancer early detection (MCED) test performance and safety from its registrational PATHFINDER 2 study at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Oct. 17-21, 2025. The PATHFINDER 2 study, conducted under an FDA-approved investigational device exemption application, is the largest MCED interventional st</description>
</item>
</channel>
</rss>